tiprankstipranks
Fate Therapeutics reports Q1 EPS (47c), consensus (49c)
PremiumThe FlyFate Therapeutics reports Q1 EPS (47c), consensus (49c)
17d ago
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
PremiumPress Releases
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
17d ago
Fate Therapeutics Advances in Autoimmune and Cancer Therapies
PremiumCompany Announcements
Fate Therapeutics Advances in Autoimmune and Cancer Therapies
17d ago
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
PremiumPress ReleasesFate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
1M ago
Fate Therapeutics files to sell 3.64M shares of common stock for holders
PremiumThe Fly
Fate Therapeutics files to sell 3.64M shares of common stock for holders
1M ago
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
PremiumPress Releases
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
2M ago
Fate Therapeutics to Present at Upcoming March Investor Conferences
PremiumPress ReleasesFate Therapeutics to Present at Upcoming March Investor Conferences
3M ago
Fate Therapeutics price target lowered to $11 from $13 at Canaccord
PremiumThe Fly
Fate Therapeutics price target lowered to $11 from $13 at Canaccord
3M ago
Fate Therapeutics price target raised to $7 from $3 at Wedbush
PremiumThe Fly
Fate Therapeutics price target raised to $7 from $3 at Wedbush
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100